Researchers to present event-free and overall survival results from NeoALTTO trial
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial are to be presented ...
Dec 11, 2013
0
0